Last reviewed 2026-04-20 · How we verify

Celdex (BETADEX)

BETADEX (Celdex) is a marketed drug that operates by binding to and stabilizing a specific protein or molecule in the body. A key strength of BETADEX is its protected intellectual property, with the key composition patent expiring in 2028. The primary risk is the eventual loss of exclusivity post-2028, which could lead to increased competition.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C (PHASE1,PHASE2)
• Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD. (PHASE2)
• Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD (PHASE2)
• A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury (PHASE2)
• The Androtriol Injection for the Treatment of Acute Ischemic Stroke (PHASE2)
• A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers (PHASE1)
• Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1 (PHASE3)
• Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Celdex CI brief — competitive landscape report
• Celdex updates RSS · CI watch RSS